

Artificial Intelligence (AI) and Machine Learning

Businesses adopting artificial intelligence and machine learning technologies and the companies developing them turn to us to navigate regulatory complexities, potential liabilities, and transactional considerations they face on the path to realizing AI's tremendous potential.

We bring together our extensive technical backgrounds and broad range of subject matter experience to help them:

- identify potential risks through data protection impact assessments;
- navigate whether AI's role is categorized as a medical device by the FDA;
- maneuver through ambiguous FDA guidelines related to AI in drug development;
- counsel on the murky landscape of copyright law in connection with generative AI;
- comply with digital communication laws regarding the use of AI systems in content moderation and advertising;
- ensure the use of AI systems is done in an ethical and responsible fashion;
- mitigate risks from contractual, e-discovery, product liability, regulatory, and tort-based claims; and
- complement their businesses and expand into new markets through investments in and acquisitions of sophisticated AI platforms.

From major corporations to emerging growth companies and their investors, we provide this guidance across the full range of AI/ML technologies including:

• fraud detection and digital identity;

Capability Lawyers



Carolyn Zander Alford New York



John M. Anderson *Atlanta*



Lisa M. Dwyer Washington, D.C.



Amanda J. Klingler Washington, D.C.



Phyllis B. Sumner Atlanta



Ronni D. Solomon Atlanta

- digital health and personalized medicine;
- chatbots;
- e-commerce and marketplace platforms;
- facial/biometric data recognition;
- intelligent robotics;
- autonomous vehicles;
- data set licensing; and more.

Cases & Deals

January 17, 2025

ServiceNow to Acquire Al Native Conversation Data

Analysis Platform Cuein

VIEW ALL

Insights

ARTICLE

January 14, 2025

Generative AI in Law: Understanding the Latest

Professional Guidelines

ARTICLE

January 13, 2025

Outlook 2025: Look for MA Cases Based on Claim Denials; Incoming DOJ May Tweak Guidance

CLIENT ALERT

January 10, 2025

FDA Releases Draft Guidance on Submission Recommendations for Al-Enabled Device Software Functions

VIEW ALL

Events

SPEAKING ENGAGEMENT

January 22, 2025

Kassi Burns to Speak at myLawCLE webinar

SPEAKING ENGAGEMENT

December 11, 2024

Michael Galdo to Speak at 15th Annual NextGen Payments & RegTech Forum

SPEAKING ENGAGEMENT

November 19, 2024

Michael Galdo to Speak at Sandpiper Partners

Cybersecurity and Trade Secrets: Protection and Litigation

2024-2025 Conference

VIEW ALL

News

PRESS RELEASE

January 15, 2025

Lauren Roth, Former Leader of FDA's Office of Policy, Joins King & Spalding's FDA and Life Sciences Team

IN THE NEWS

December 11, 2024

Jeff Telep, Shaswat Das, Emily Gordy, Ashley Parrish, Daniel Kahan, Brent Gilfedder, Dan Daneshrad, Randall Robinson and Lucas Queiroz Pires's Client Alert and Rob Hur, Leah Grossi and Michael Galdo's Client Alert are referenced in Corporate Compliance Insights' round-up of the top stories of 2024

RECOGNITION

December 10, 2024
Financial Times Honors King & Spalding with its
Innovation in Digital Legal Products Award

VIEW ALL